Key facts today
A U.S. investigation into pharmaceutical imports may affect AstraZeneca's first-quarter results. Analysts believe AstraZeneca is well-protected from potential tariff risks linked to this inquiry.
AstraZeneca faces challenges from the U.S.-China trade war, as China raises tariffs on U.S. goods to 125%, which may raise costs for drugmakers.
AstraZeneca stands out for its transparency in sharing details about its manufacturing and drug-making processes, unlike many companies in the electronics sector that are less forthcoming.
0.80 USD
6.25 B USD
48.03 B USD
About ASTRAZENECA PLC ORD USD0.25
Sector
Industry
CEO
Pascal Soriot
Website
Headquarters
Cambridge
Founded
1992
ISIN
ARDEUT112489
FIGI
BBG000DDGBJ4
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Supply and Demand Trading Made Simple With Astrazeneca StockIn the ever-evolving world of stock trading, where news headlines can shift markets in a heartbeat, savvy investors often turn to the age-old principles of supply and demand to find clarity. Enter AstraZeneca stock (NASDAQ: AZN) — a biopharmaceutical titan that has played a pivotal role in global he
Astrazeneca potentially to $88AstraZeneca’s share price has been hovering around a long-term trend line established since 2017. Historically, each time the price has tested this trend line, it has rebounded sharply, suggesting strong investor confidence.
From 2017 to 2023, the company’s financial performance has been notably ro
BULLISH ON AZNAstraZeneca's Q3 2024 earnings exceeded expectations, with a revenue increase of 18%, signaling healthy demand for its products, especially in oncology and rare diseases.
Technicals - Key Indicators:
RSI (Relative Strength Index): Currently at 41.08, indicating strong bullish momentum but not ye
Astrazeneca (Wait for correction to complete)Hello,
To demonstrate how we can leverage TradingView for informed investment decisions, let’s analyze AstraZeneca as our example today. I will follow a structured approach and provide an investment recommendation based on both fundamental and technical insights.
Understanding the Business
Befor
AZN eyes on $71: Double Fib support that could launch a leg up AZN daily chart shows a significant pullback.
Currently testing a double Fib (Genesis+Covid).
Long entry option with a tight SL just below fibs.
$ 70.95-71.01 is the tight support of interest.
$ 80.48-81.11 would be an optimistic target.
===========================================
.
AstraZeneca - GBP | Chart & Forecast SummaryKey Indicators on Trade Set Up in General
1. Push Set Up
2. Range Set up
3. Break & Retest Set Up
Active Sessions on Relevant Range & Elemented Probabilities;
* Asian(Ranging) - London(Upwards) - NYC(Downwards)
* Weekend Crypto Session
Trend | Time Frame Conductive | Weekly Time Frame
- General Tr
AZN Astrazeneca plc ADRI’ve been closely monitoring AZN, which has been trading on the upside for a while now. Given the recent momentum, it appears to be approaching a point where a downward move could be imminent. I believe the stock might be ready to take a dip, presenting a potential opportunity for a downside play.
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where AZND is featured.